Cargando…
23andMe: a new two-sided data-banking market model
BACKGROUND: Since 2006, the genetic testing company 23andMe has collected biological samples, self-reported information, and consent documents for biobanking and research from more than 1,000,000 individuals (90 % participating in research), through a direct-to-consumer (DTC) online genetic-testing...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826522/ https://www.ncbi.nlm.nih.gov/pubmed/27059184 http://dx.doi.org/10.1186/s12910-016-0101-9 |
_version_ | 1782426347183800320 |
---|---|
author | Stoeklé, Henri-Corto Mamzer-Bruneel, Marie-France Vogt, Guillaume Hervé, Christian |
author_facet | Stoeklé, Henri-Corto Mamzer-Bruneel, Marie-France Vogt, Guillaume Hervé, Christian |
author_sort | Stoeklé, Henri-Corto |
collection | PubMed |
description | BACKGROUND: Since 2006, the genetic testing company 23andMe has collected biological samples, self-reported information, and consent documents for biobanking and research from more than 1,000,000 individuals (90 % participating in research), through a direct-to-consumer (DTC) online genetic-testing service providing a genetic ancestry report and a genetic health report. However, on November 22, 2013, the Food and Drug Administration (FDA) halted the sale of genetic health testing, on the grounds that 23andMe was not acting in accordance with federal law, by selling tests of undemonstrated reliability as predictive tests for medical risk factors. Consumers could still obtain the genetic ancestry report, but they no longer had access to the genetic health report in the United States (US). However, this did not prevent the company from continuing its health research, with previously obtained and future samples, provided that consent had been obtained from the consumers concerned, or with health reports for individuals from other countries. Furthermore, 23andMe was granted FDA authorization on February 19, 2015, first to provide reports about Bloom syndrome carrier status, and, more recently, to provide consumers with “carrier status” information for 35 genes known (with high levels of confidence) to cause disease. DISCUSSION: In this Debate, we highlight the likelihood that the primary objective of the company was probably two-fold: promoting itself within the market for predictive testing for human genetic diseases and ancestry at a low cost to consumers, and establishing a high-value database/biobank for research (one of the largest biobanks of human deoxyribonucleic acid (DNA) and personal information). SUMMARY: By dint of this marketing approach, a two-sided market has been established between the consumer and the research laboratories, involving the establishment of a database/DNA biobank for scientific and financial gain. We describe here the profound ethical issues raised by this setup. |
format | Online Article Text |
id | pubmed-4826522 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-48265222016-04-10 23andMe: a new two-sided data-banking market model Stoeklé, Henri-Corto Mamzer-Bruneel, Marie-France Vogt, Guillaume Hervé, Christian BMC Med Ethics Debate BACKGROUND: Since 2006, the genetic testing company 23andMe has collected biological samples, self-reported information, and consent documents for biobanking and research from more than 1,000,000 individuals (90 % participating in research), through a direct-to-consumer (DTC) online genetic-testing service providing a genetic ancestry report and a genetic health report. However, on November 22, 2013, the Food and Drug Administration (FDA) halted the sale of genetic health testing, on the grounds that 23andMe was not acting in accordance with federal law, by selling tests of undemonstrated reliability as predictive tests for medical risk factors. Consumers could still obtain the genetic ancestry report, but they no longer had access to the genetic health report in the United States (US). However, this did not prevent the company from continuing its health research, with previously obtained and future samples, provided that consent had been obtained from the consumers concerned, or with health reports for individuals from other countries. Furthermore, 23andMe was granted FDA authorization on February 19, 2015, first to provide reports about Bloom syndrome carrier status, and, more recently, to provide consumers with “carrier status” information for 35 genes known (with high levels of confidence) to cause disease. DISCUSSION: In this Debate, we highlight the likelihood that the primary objective of the company was probably two-fold: promoting itself within the market for predictive testing for human genetic diseases and ancestry at a low cost to consumers, and establishing a high-value database/biobank for research (one of the largest biobanks of human deoxyribonucleic acid (DNA) and personal information). SUMMARY: By dint of this marketing approach, a two-sided market has been established between the consumer and the research laboratories, involving the establishment of a database/DNA biobank for scientific and financial gain. We describe here the profound ethical issues raised by this setup. BioMed Central 2016-03-31 /pmc/articles/PMC4826522/ /pubmed/27059184 http://dx.doi.org/10.1186/s12910-016-0101-9 Text en © Stoeklé et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Debate Stoeklé, Henri-Corto Mamzer-Bruneel, Marie-France Vogt, Guillaume Hervé, Christian 23andMe: a new two-sided data-banking market model |
title | 23andMe: a new two-sided data-banking market model |
title_full | 23andMe: a new two-sided data-banking market model |
title_fullStr | 23andMe: a new two-sided data-banking market model |
title_full_unstemmed | 23andMe: a new two-sided data-banking market model |
title_short | 23andMe: a new two-sided data-banking market model |
title_sort | 23andme: a new two-sided data-banking market model |
topic | Debate |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826522/ https://www.ncbi.nlm.nih.gov/pubmed/27059184 http://dx.doi.org/10.1186/s12910-016-0101-9 |
work_keys_str_mv | AT stoeklehenricorto 23andmeanewtwosideddatabankingmarketmodel AT mamzerbruneelmariefrance 23andmeanewtwosideddatabankingmarketmodel AT vogtguillaume 23andmeanewtwosideddatabankingmarketmodel AT hervechristian 23andmeanewtwosideddatabankingmarketmodel |